Ballal Rahul D.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Apr 12, 2024
- Accession no.
- 0001415889-24-010777
- Filed
- Apr 12, 2024
- Trade date
- Apr 10-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.57M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ballal Rahul D.CIK 0001805097 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2024 | Common Stock | MOption exerciseAcquired | +13,600 | $12.60 | +$171,360 | 35,941 | Direct | |
| Apr 10, 2024 | Common Stock | SSaleDisposed | −13,600 | $21.01F2 | −$285,736 | 22,341 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseAcquired | +48,820 | $12.60 | +$615,132 | 71,161 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseAcquired | +4,580 | $19.68 | +$90,134.4 | 75,741 | Direct | |
| Apr 11, 2024 | Common Stock | SSaleDisposed | −30,300 | $23.14F3 | −$701,142 | 45,441 | Direct | |
| Apr 11, 2024 | Common Stock | SSaleDisposed | −20,032 | $25.00F4 | −$500,800 | 25,409 | Direct | |
| Apr 11, 2024 | Common Stock | SSaleDisposed | −3,068 | $25.21F5 | −$77,344.28 | 22,341 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2024 | Common Stock | MOption exerciseDisposed | −13,600 | $0.00 | $0 | 48,820 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseDisposed | −48,820 | $0.00 | $0 | 0 | Direct | |
| Apr 11, 2024 | Common Stock | MOption exerciseDisposed | −4,580 | $0.00 | $0 | 75,742 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.